Exhibit 16.1

April 27, 2017

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Commissioners:  

We have read the statements made by Anika Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K, as part of the Form 8-K of Anika Therapeutics, Inc. dated April 24, 2017. We agree with the statements concerning our Firm in such Form 8-K.

Very truly yours,

PricewaterhouseCoopers LLP

Boston, Massachusetts

Attachment

· The reports of PwC on the Company’s consolidated financial statements for the fiscal years ended December 31, 2016 and 2015 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or accounting principles.

· During the fiscal years ended December 31, 2016 and 2015, and in the subsequent interim period through April 24, 2017, there were: (a) no disagreements with PwC on any matters of accounting principles or practices, financial statement disclosure or auditing scope or procedure which disagreements, if not resolved to the satisfaction of PwC, would have caused PwC to make reference to the matter in their reports on the consolidated financial statements for such years; and (b) no reportable events (as defined in Item 304(a)(1)(v) of Regulation S-K).